These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 19968600)

  • 1. Metalloproteinases and their inhibitors-diagnostic and therapeutic opportunities in orthopedics.
    Pasternak B; Aspenberg P
    Acta Orthop; 2009 Dec; 80(6):693-703. PubMed ID: 19968600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix metalloproteinases (MMPs) in health and disease: an overview.
    Malemud CJ
    Front Biosci; 2006 May; 11():1696-701. PubMed ID: 16368548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MMPs and ADAMs/ADAMTS inhibition therapy of abdominal aortic aneurysm.
    Li Y; Wang W; Li L; Khalil RA
    Life Sci; 2020 Jul; 253():117659. PubMed ID: 32283055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix Metalloproteinases: How Much Can They Do?
    Ågren MS; Auf dem Keller U
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32290531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
    Ulrich D; Hrynyschyn K; Pallua N
    Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A complete expression profile of matrix-degrading metalloproteinases in Dupuytren's disease.
    Johnston P; Chojnowski AJ; Davidson RK; Riley GP; Donell ST; Clark IM
    J Hand Surg Am; 2007 Mar; 32(3):343-51. PubMed ID: 17336841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of MMPs and ADAM/ADAMTS.
    Malemud CJ
    Biochem Pharmacol; 2019 Jul; 165():33-40. PubMed ID: 30826330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactive site mutations in tissue inhibitor of metalloproteinase-3 disrupt inhibition of matrix metalloproteinases but not tumor necrosis factor-alpha-converting enzyme.
    Wei S; Kashiwagi M; Kota S; Xie Z; Nagase H; Brew K
    J Biol Chem; 2005 Sep; 280(38):32877-82. PubMed ID: 16079149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteinases and plaque rupture: unblocking the road to translation.
    Newby AC
    Curr Opin Lipidol; 2014 Oct; 25(5):358-66. PubMed ID: 25089553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular diseases.
    Castro MM; Kandasamy AD; Youssef N; Schulz R
    Pharmacol Res; 2011 Dec; 64(6):551-60. PubMed ID: 21689755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Disintegrin and Metalloproteinase (ADAM) and ADAM with thrombospondin motifs (ADAMTS) family in vascular biology and disease.
    Zhong S; Khalil RA
    Biochem Pharmacol; 2019 Jun; 164():188-204. PubMed ID: 30905657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix metalloproteinases and their inhibitors in bone: an overview of regulation and functions.
    Varghese S
    Front Biosci; 2006 Sep; 11():2949-66. PubMed ID: 16720367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MMPs and ADAMs in neurological infectious diseases and multiple sclerosis.
    Muri L; Leppert D; Grandgirard D; Leib SL
    Cell Mol Life Sci; 2019 Aug; 76(16):3097-3116. PubMed ID: 31172218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metalloproteinases: A parade of functions in matrix biology and an outlook for the future.
    Apte SS; Parks WC
    Matrix Biol; 2015; 44-46():1-6. PubMed ID: 25916966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dual inhibitor of matrix metalloproteinases and a disintegrin and metalloproteinases, [¹⁸F]FB-ML5, as a molecular probe for non-invasive MMP/ADAM-targeted imaging.
    Matusiak N; Castelli R; Tuin AW; Overkleeft HS; Wisastra R; Dekker FJ; Prély LM; Bischoff R; van Waarde A; Dierckx RA; Elsinga PH
    Bioorg Med Chem; 2015 Jan; 23(1):192-202. PubMed ID: 25438884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insights into the activity, differential expression, mutual regulation, and functions of matrix metalloproteinases and a disintegrin and metalloproteinases in hypertension and cardiac disease.
    Berry E; Bosonea AM; Wang X; Fernandez-Patron C
    J Vasc Res; 2013; 50(1):52-68. PubMed ID: 23172306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs.
    Jabłońska-Trypuć A; Matejczyk M; Rosochacki S
    J Enzyme Inhib Med Chem; 2016; 31(sup1):177-183. PubMed ID: 27028474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metalloproteinases and their inhibitors in neurological disease.
    Lopez-Navarro ER; Gutierrez J
    Naunyn Schmiedebergs Arch Pharmacol; 2022 Jan; 395(1):27-38. PubMed ID: 34851449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diverse Functions of a Disintegrin and Metalloproteinase with Thrombospondin Motif-1].
    Hirohata S; Inagaki J; Ohtsuki T
    Yakugaku Zasshi; 2017; 137(7):811-814. PubMed ID: 28674292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Introduction: MMPs, ADAMs/ADAMTSs research products to achieve big dream.
    Okazaki I; Nabeshima K
    Anticancer Agents Med Chem; 2012 Sep; 12(7):688-706. PubMed ID: 22292751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.